Alefacept: where it stands today

Bibliography

• van de Kerkhof P, Griffiths CE, Christophers E, Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology 2005;211:256-63
   PubMed Web of Science ®Google Scholar
• Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37
   PubMed Web of Science ®Google Scholar
• Zachariae H, Kragballe K, Hansen HE, Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997;136:531-5
   PubMed Web of Science ®Google Scholar
• Gottlieb AB. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg 2004;8(Suppl 2):14-9
   PubMed Web of Science ®Google Scholar
• Van der Rhee HJ TJ, Herrman WA, Waterman AH, Polano MK. Combined treatment of psoriasis with a new aromatic retinoid (Tiagson) in low dosage orally and triamcinalone acetonide cream topically: a double-blind trial. Br J Dermatol 1980;102:203-12
   PubMed Web of Science ®Google Scholar
• Stern RS LN, Melski J, Parrish JA, Cutaneous squamus-cell carcinoma in patients treated with PUVA. N Engl J Med 1984;310:1156-61
   PubMed Web of Science ®Google Scholar
• Horn EJ, Fox KM, Patel V, Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol 2007;57:957-62
   PubMed Web of Science ®Google Scholar
• Alefacept Approval Letter 1/30/03. FDA/Office of Therapeutics Research and Review, 2003. Available from www.fda.gov/DevelopmentApprovalProcess/HowDrugsareDeveloped andApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm128088.htm). [Accessed 2003]
   Google Scholar
• Gottlieb A, Korman NJ, Gordon KB, Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Dray L, A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy 2009;11:61-7
   PubMed Web of Science ®Google Scholar
• AMEVIVE (alefacept) package insert Biogen, INC. Available from: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsare DevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm086009.pdf). [Accessed 2003]
   Google Scholar
• Goedkoop AY, de Rie MA, Picavet DI, Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res 2004;295:465-73
   PubMed Web of Science ®Google Scholar
• Prasertsuntarasai T, Bello EF. Mycobacterium avium complex olecranon bursitis in a patient treated with alefacept. Mayo Clin Proc 2005;80:1532-3
   PubMed Web of Science ®Google Scholar
• Thaci D, Patzold S, Kaufmann R, Boehncke WH. Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. Br J Dermatol 2005;152:1048-50
   PubMed Web of Science ®Google Scholar
• da Silva AJ, Brickelmaier M, Majeau GR, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells. J Immunol 2002;168:4462-71
   PubMed Web of Science ®Google Scholar
• Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55
   PubMed Web of Science ®Google Scholar
• Cooper JC, Morgan G, Harding S, Alefacept selectively promotes NK cell-mediated deletion of CD45R0+ human T cells. Eur J Immunol 2003;33:666-75
   PubMed Web of Science ®Google Scholar
• Vaishnaw AK, TenHoor CN. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 2002;29:415-26
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Casale TB, Frankel E, CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003;49:816-25
   PubMed Web of Science ®Google Scholar
• Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003;4:131-9
   PubMed Web of Science ®Google Scholar
• Lowe NJ, Gonzalez J, Bagel J, Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003;42:224-30
   PubMed Web of Science ®Google Scholar
• Krueger GG, Papp KA, Stough DB, A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27
   PubMed Web of Science ®Google Scholar
• Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003;206:307-15
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Lebwohl M, Em Griffiths C. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003;13:117-23
   PubMed Web of Science ®Google Scholar
• Menter A, Cather JC, Baker D, The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006;54:61-3
   PubMed Web of Science ®Google Scholar
• Gribetz CH, Blum R, Brady C, An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005;53:73-5
   PubMed Web of Science ®Google Scholar
• Cafardi JA, Cantrell W, Wang W, The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis. Skinmed 2008;7:67-72
   PubMedGoogle Scholar
• Krell J, Nelson C, Spencer L, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol 2008;58:609-16
   PubMed Web of Science ®Google Scholar
• Korver JE, Langewouters AM, Van De Kerkhof PC, Pasch MC. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006;20:1252-5
   PubMed Web of Science ®Google Scholar
• Brimhall AK, King LN, Licciardone JC, Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:274-85
   PubMed Web of Science ®Google Scholar
• Goffe B, Papp K, Gratton D, An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005;27:1912-21
   PubMed Web of Science ®Google Scholar
• Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008;58:984-9
   PubMed Web of Science ®Google Scholar
• Simon D, Wittwer J, Kostylina G, Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423-4
   PubMed Web of Science ®Google Scholar
• O'Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 2008;37:575-81
   PubMed Web of Science ®Google Scholar
• Chang AL, Badger J, Rehmus W, Kimball AB. Alefacept for erosive lichen planus: a case series. J Drugs Dermatol 2008;7:379-83
   PubMed Web of Science ®Google Scholar
• Kraan MC, van Kuijk AW, Dinant HJ, Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002;46:2776-84
   PubMed Web of Science ®Google Scholar
• Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009;60:402-11
   PubMed Web of Science ®Google Scholar
• Heffernan MP, Hurley MY, Martin KS, Alefacept for alopecia areata. Arch Dermatol 2005;141:1513-6
   PubMed Web of Science ®Google Scholar
• Foss CE, Clark AR, Inabinet R, An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2008;22:943-9
   PubMed Web of Science ®Google Scholar
• Guenther LC. Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis. J Cutan Med Surg 2007;11:202-5
   PubMed Web of Science ®Google Scholar
• Carr D, Tusa MG, Carroll CL, Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatolog Treat 2008;19:97-100
   PubMed Web of Science ®Google Scholar
• Myers W, Christiansen L, Gottlieb AB. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 2005;53:S127-9
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Bitan M, Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. Bone Marrow Transplant 2005;36:1097-101
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Dray L, A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. Cytotherapy 2009;11:61-7
   PubMed Web of Science ®Google Scholar
• Shapira MY, Abdul-Hai A, Resnick IB, Alefacept treatment for refractory chronic extensive GVHD. Bone Marrow Transplant 2009;43:339-43
   PubMed Web of Science ®Google Scholar
• Stotler CJ, Eghtesad B, Hsi E, Silver B. Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. Blood 2009;113:5365-6
   PubMed Web of Science ®Google Scholar
• Hurd DS, Johnston C, Bevins A. A case report of Hailey-Hailey disease treated with alefacept (Amevive). Br J Dermatol 2008;158:399-401
   PubMed Web of Science ®Google Scholar
• Garcia-Zuazaga J, Korman NJ. Cutaneous sarcoidosis successfully treated with alefacept. J Cutan Med Surg 2006;10:300-3
   PubMed Web of Science ®Google Scholar
• Al-Mutairi N, Al-Doukhi A. Familial coexisting and colocalized psoriasis and vitiligo responding to alefacept. J Cutan Med Surg 2009;13:172-5
   PubMed Web of Science ®Google Scholar
• Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine - Levels of Evidence. 2009. Available from: http://www.cebm.net/index.aspx?o=1025
   Google Scholar